Phase 3 study of ACER-003 for systemic scleroderma

Trial Profile

Phase 3 study of ACER-003 for systemic scleroderma

Planning
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Acetylcysteine (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2016 According to Acer Therapeutics website, the company plans to initiate the trial in the second quarter of 2016 and complete in approximately first quarter of 2019.
    • 20 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top